ZOETIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 169 USD | +0.54% |
|
+1.18% | -14.35% |
| May. 08 | HSBC Adjusts Price Target on Zoetis to $225 From $230 | MT |
| May. 06 | BNP Paribas Exane Adjusts Price Target on Zoetis to $232 From $237 | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 9.15B | Sales 2025 * | 9.77B | Capitalization | 77.13B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.51B | Net income 2025 * | 2.76B | EV / Sales 2024 * | 8.9 x |
| Net Debt 2024 * | 4.31B | Net Debt 2025 * | 3.75B | EV / Sales 2025 * | 8.28 x |
| P/E ratio 2024 * |
30.9
x | P/E ratio 2025 * |
28
x | Employees | 14,100 |
| Yield 2024 * |
1.02% | Yield 2025 * |
1.16% | Free-Float | 90.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zoetis Inc.
More recommendations
More press releases
More news
| 1 day | +0.54% | ||
| 1 week | +1.18% | ||
| Current month | +6.15% | ||
| 1 month | +3.88% | ||
| 3 months | -14.33% | ||
| 6 months | -0.17% | ||
| Current year | -14.35% |
1 week
161.00
172.23
1 month
144.80172.23
Current year
144.80200.53
1 year
144.80201.92
3 years
124.15249.27
5 years
90.14249.27
10 years
30.24249.27
| Managers | Title | Age | Since |
|---|---|---|---|
Kristin Peck
CEO | Chief Executive Officer | 52 | 11-12-31 |
Wetteny Joseph
DFI | Director of Finance/CFO | 52 | 21-05-31 |
Mike McFarland
CTO | Chief Tech/Sci/R&D Officer | - | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 12-12-31 | |
Louise Parent
BRD | Director/Board Member | 73 | 13-07-31 |
Robert Scully
BRD | Director/Board Member | 74 | 13-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.87% | 1 M€ | -.--% | ||
| 3.35% | 0 M€ | +7.69% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 169 | +0.54% | 2,010,749 |
| 24-05-09 | 168.1 | +1.95% | 2,145,422 |
| 24-05-08 | 164.9 | -2.10% | 4,673,075 |
| 24-05-07 | 168.4 | +1.51% | 3,337,509 |
| 24-05-06 | 166 | -0.67% | 3,081,343 |
Delayed Quote Nyse, May 10, 2024 at 04:00 pm EDT
More quotes
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows:
- pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%);
- livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%);
- other (1.1%).
Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%).
At the end of 2022, the group has 29 production sites worldwide.
The United States accounts for 53.4% of net sales.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
169
USD
Average target price
211
USD
Spread / Average Target
+24.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.35% | 77.13B | |
| +14.09% | 8.4B | |
| +27.62% | 3.79B | |
| -0.70% | 3.22B | |
| +14.70% | 1.64B | |
| -10.12% | 1.5B | |
| -22.60% | 1.3B | |
| -4.20% | 1.25B | |
| -10.26% | 1.18B | |
| +5.06% | 1.1B |
- Stock Market
- Equities
- ZTS Stock
